Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(11):733-735; doi:10.1093/jnci/djj253
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vastag, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vastag, B.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Raloxifene Prevails in STAR Trial, May Face Easier Road to Acceptance Than Previous Drugs

Brian Vastag

The first 10% of the full text of this article appears below.

Raloxifene seems to have won the contest with tamoxifen to prevent breast cancer in high-risk postmenopausal women, providing equal cancer-preventing benefits with fewer serious side effects. The finding clears the way for possibly wider use of the osteoporosis drug.

Results from the 20,000-woman Study of Tamoxifen and Raloxifene (STAR) were released in April, more than a year ahead of schedule. Raloxifene's greatest advantage appears to be fewer serious side effects, including uterine cancer, blood clots, and cataracts.

"The study was designed to compare the drugs head to head, and raloxifene was the winner," said Larry Wickerham, M.D., associate director of the National Surgical Adjuvant Breast and Bowel Project, which announced the results with the National Cancer Institute

"This is good news for women," added Leslie Ford, M.D., associate director of clinical research for NCI's Division of Cancer Prevention. Roughly the same number of women . . . [Full Text of this Article]

Fewer Adverse Events

A Running Start


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

NCI Director Opts Against Breast Cancer Prevention Trial In Favor of Biomarkers
Liz Savage
J Natl Cancer Inst 2007 99: 1282-1289. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Decision AnalysisHome page
G. B. Hazen and M. Huang
Parametric Sensitivity Analysis Using Large-Sample Approximate Bayesian Posterior Distributions
Decision Analysis, December 1, 2006; 3(4): 208 - 219.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. A. Johnson
The SERM of My Dreams.
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3754 - 3756.
[Full Text] [PDF]